HIV breakthrough? antibody cocktail aims to replace daily meds
NCT ID NCT05245292
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested whether a single infusion of two long-acting antibodies plus repeated injections of an immune-stimulating drug can keep HIV under control after people stop their daily antiretroviral therapy. Twenty-eight adults with well-controlled HIV participated. The goal was to see if the combination is safe and can delay or prevent the virus from rebounding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
two broadly neutralizing antibodies (3BNC117-LS and 10-1074-LS) plus an IL-15 superagonist (N-803)
What this could lead to
If successful, this could point toward a way for people with HIV to stop daily antiretroviral therapy while keeping the virus under control.
What could go wrong
This is a very early, small Phase 1 trial with only 28 participants, so results may not apply widely. The treatment may not prevent viral rebound, and side effects from the antibodies or immune stimulant are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman School of Medicine University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
The Rockefeller University
New York, New York, 10065, United States
-
Weill Cornell Medicine, Cornell Clinical Trials Unit
New York, New York, 10021, United States